Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

PlayVIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a). Now the…

read more »
PlayHow best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

Professor Gaetano De Ferrari (University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) discusses the importance of patient characteristics, and the timing and history of vascular disease.

read more »
PlayWhat’s in the PCSK9 pipeline?

What’s in the PCSK9 pipeline?

PCSK9 antibody therapy is indisputably effective, well tolerated and improves clinical outcomes; however, cost is an issue. PCSK9 Forum Editor Professor Derick Raal (University of Witwatersrand, Johnannesburg, South Africa) discusses what to look forward to after the PCSK9 monoclonal antibodies.

read more »
PlayEAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?

EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?

Professor Henry Ginsberg (Columbia University, New York, USA) discusses the late breaker genetics analysis reported at EAS Congress.

read more »
PlayEAS Consensus Panel: Statins do not impair cognitive function

EAS Consensus Panel: Statins do not impair cognitive function

EAS Panel Co-Chair discusses the evidence-based conclusions from this latest EAS Consensus Panel statement on adverse effects of statin therapy, focusing on effects on cognitive function.

read more »
PlayEAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)

EAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)

Dr Michelle O’Donogue (Brigham and Women’s Hospital, Boston, USA) discusses the key findings from this FOURIER analysis and what it means for patients

read more »